Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Clinicians, investigators and cancer patients now have access to a new online search tool that provides more detailed information about clinical research trials available for cancer patients.
Eleven Vanderbilt University faculty members named to endowed chairs were honored Oct. 23 during a festive celebration at the Student Life Center.
Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.
An estimated 8,000 participants enjoyed a sunny sky, warm temperature and live music during the 25th annual Greater Nashville Heart Walk on Saturday, Oct. 14.